Publications scientifiques en 2018

Depuis le 02/06/2023
  1. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
    Gouverneur A, Salvo F, Berdaï D, Moore N, Fourrier-Réglat A, Noize P.
    J Geriatr Oncol. 2018
  2. Atropinic (Anticholinergic) Burden in Antipsychotic-Treated Patients.
    Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, Durrieu G, Arbus C, Schmitt L, Bé gaud B, Montastruc JL.
    Fundam Clin Pharmacol. 2018
  3. Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users.
    Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A.
    Eur J Clin Pharmacol. 2018
  4. Adverse drug reactions of analgesic medicines: analysis of the Romanian pharmacovigilance database.
    Cazacu I, Stroe R, Dondera R, Mogosan C, Haramburu F, Fourrier-Réglat A, Loghin F.
    Fundam Clin Pharmacol. 2018
  5. Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions .
    Deljehier T, Pariente A, Miremont-Salamé G, Haramburu F, Nguyen L, Rubin S, Rigothier C, Théophile H.
    Br J Clin Pharmacol. 2018
  6. Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics.
    Moore N, Scheiman JM.
    Postgrad Med. 2018
  7. Detection of drug safety signals from clinical trials data: Role of SUSARs.
    Perez C, Olivier P, Lortal B, Duranton S, Montastruc JL, Colin AL, Toulza E, Becker M, Hamy L, Crepin S, Roussillon C, Gimbert A, Petitpain N, Salvo F.
    Pharmacol Res. 2018
  8. Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis.
    Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, Bégaud B.
    Vaccine. 2018
  9. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
    Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, Moore N, Fourrier-Réglat A, Smith D; EREBUS Study Group.
    Clin Colorectal Cancer. 2018
  10. Impact of cancer diagnosis on persistence of oral antidiabetic drugs.
    Létinier L, Mansiaux Y, Pariente A, Fourrier-Réglat A.
    Diabetes Res Clin Pract. 2018
  11. Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases.
    Berdaï D, Thomas-Delecourt F, Szwarcensztein K, d'Andon A, Collignon C, Comet D, Déal C, Dervaux B, Gaudin AF, Lamarque-Garnier V, Lechat P, Marque S, Maugendre P, Méchin H, Moore N, Nachbaur G, Robain M, Roussel C, Tanti A, Thiessard F.
    Therapie . 2018
  12. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.
    Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M.
    Eur Respir J. 2018
  13. Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database.
    Mouchet J, Bégaud B.
    Drug Saf. 2018
  14. [The nocebo effect: Various aspects and consequences in clinical practice]
    Mouly S, Bergmann JF, Molimard M.
    Rev Med Interne. 2018
  15. Tamper-resistant prescription forms for narcotics in France: should we generalise them?
    Daveluy A, Sauvaget L, Bastien A, Lapeyre-Mestre M, Collin C, Richard N, Haramburu F.
    Fundam Clin Pharmacol. 2018
  16. Non-communicable diseases in Indian slums: re-framing the Social Determinants of Health.
    Lumagbas LB, Coleman HLS, Bunders J, Pariente A, Belonje A, de Cock Buning T.
    Glob Health Action. 2018
  17. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.
    Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, Moretti U.
    Nutr Metab Cardiovasc Dis. 2018
  18. Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study.
    Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Bégaud B, Pariente A.
    Br J Clin Pharmacol. 2018
  19. Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis.
    Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, Bégaud B.
    Pharmacol Res. 2018
  20. [Understanding the distrust towards the assessment of medicines. Beyond conflict of interests]
    Tournay V, Pariente A.
    Therapie. 2018
  21. Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis.
    Maura G, Billionnet C, Coste J, Weill A, Neumann A, Pariente A.
    Drug Saf. 2018
  22. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
    Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE.
    Heart. 2018
  23. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM, Bobes J, Fleischhacker WW, Heres S, Moore N, Bent-Ennakhil N, Sapin C, Loze JY, Nylander AG, Patel MX.
    Eur Psychiatry. 2018
  24. [Psychoactive substances use in Réunion Island and Mayotte, French departments in Indian Ocean]
    Daveluy A, Haramburu F.
    Therapie. 2018
  25. Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.
    Duong M, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N.
    Drug Saf. 2018
  26. Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort.
    Hurault-Delarue C, Lacroix I, Bénard-Laribière A, Montastruc JL, Pariente A, Damase-Michel C.
    Eur Arch Psychiatry Clin Neurosci. 2018
  27. Assessment of the state of pharmacovigilance in the South-South zone of Nigeria using WHO pharmacovigilance indicators.
    Opadeyi AO, Fourrier-Réglat A, Isah AO.
    BMC Pharmacol Toxicol. 2018
  28. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
    Calmettes C, Gabriel F, Blanchard E, Servant V, Bouchet S, Kabore N, Forcade E, Leroyer C, Bidet A, Latrabe V, Leguay T, Vigouroux S, Tabrizi R, Breilh D, Accoceberry I, de Lara MT, Pigneux A, Milpied N, Dumas PY.
    Oncotarget. 2018
  29. The economic burden of preventable adverse drug reactions: a systematic review of observational studies.
    Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, Ingrasciotta Y, Salvo F, Spina E, Trifirò G.
    Expert Opin Drug Saf. 2018
  30. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database.
    Billioti de Gage S, Collin C, Le-Tri T, Pariente A, Bégaud B, Verdoux H, Dray-Spira R, Zureik M.
    CNS Drugs. 2018
  31. Use of lipid-lowering drugs and the risk of cataract: a population-based nested case-control study.
    Bezin J, Mansiaux Y, Noize P, Salvo F, Bégaud B, Pariente A.
    Clin Pharmacol Ther. 2018
  32. Comorbidities and COPD severity in a clinic-based cohort.
    Raherison C, Ouaalaya EH, Bernady A, Casteigt J, Nocent-Eijnani C, Falque L, Le Guillou F, Nguyen L, Ozier A, Molimard M.
    BMC Pulm Med. 2018
  33. Biomonitoring of occupational exposure to 5-FU by assaying ?-fluoro-?-alanine in urine with a highly sensitive UHPLC-MS/MS method.
    Dhersin A, Atgé B, Martinez B, Titier K, Rousset M, Sidatt Cheikh El Moustaph M, Verdun-Esquer C, Molimard M, Villa A, Canal-Raffin M.
    Analyst. 2018
  34. Reply to 'The easy misuse of antidepressants during pregnancy is depressing'.
    Bénard-Laribière A, Sutter-Dallay AL, Pariente A.
    Br J Clin Pharmacol. 2018
  35. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study.
    Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N.
    Pharmacoepidemiol Drug Saf. 2018
  36. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G, Salvo F, Moride Y.
    Drug Saf. 2018
  37. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)]
    Baumevieille M, Perri-Plandé J, Miremont-Salamé G, Daveluy A, Haramburu F.
    Therapie. 2018
  38. Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort.
    Ziad A, Olekhnovitch R, Ruiz F, Berr C, Bégaud B, Goldberg M, Zins M, Mura T.
    J Neurol Neurosurg Psychiatry. 2018
  39. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK.
    Lancet Psychiatry. 2018
  40. Risk of Serious Trauma with Glucose-Lowering Drugs in Older Persons: A Nested Case-Control Study.
    Arnaud M, Pariente A, Bezin J, Bégaud B, Salvo F.
    J Am Geriatr Soc. 2018
  41. An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France.
    Blin P, Demoly P, Drouet M, Falissard B, Lignot-Maleyran S, Maizi H, Lorrain S, Lassalle R, Droz-Perroteau C, Moore N, Molimard M.
    Allergy Asthma Clin Immunol. 2018
  42. Authors' Reply to Cohen et al.'s Comment on "Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database".
    Mouchet J, Bégaud B.
    Drug Saf. 2018
  43. Propensity Score-Based Approaches in High Dimension for Pharmacovigilance Signal Detection: an Empirical Comparison on the French Spontaneous Reporting Database.
    Courtois É, Pariente A, Salvo F, Volatier É, Tubert-Bitter P, Ahmed I.
    Front Pharmacol. 2018
  44. Inhaled triple therapy in chronic obstructive pulmonary disease.
    Molimard M, Girodet PO, Moore N.
    Lancet. 2018
  45. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.
    Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE.
    Drug Saf. 2018
  46. Antibiotics associated with acquisition of carbapenem-resistant Pseudomonas aeruginosa in ICUs: a multicentre nested case-case-control study.
    Coppry M, Jeanne-Leroyer C, Noize P, Dumartin C, Boyer A, Bertrand X, Dubois V, Rogues AM.
    J Antimicrob Chemother. 2018
  47. [Will be 60 years the age of reason?]
    Bégaud B.
    Presse Med. 2018
  48. Interest of pharmacoepidemiology for the study of inhaled drugs .
    Molimard M, Girodet PO, Van Ganse E.
    Therapie. 2018
  49. A history of pharmacoepidemiology.
    Bégaud B.
    Therapie. 2018
  50. Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database.
    Bosco-Lévy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, Blin P, Chatellier G, Looten V, Moore N.
    Pharmacoepidemiol Drug Saf. 2018
  51. Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non-valvular atrial fibrillation.
    Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
    Br J Clin Pharmacol. 2018
  52. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
    Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ.
    Lancet Oncol. 2018
  53. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD.
    Kocks JWH, Chrystyn H, van der Palen J, Thomas M, Yates L, Landis SH, Driessen MT, Gokhale M, Sharma R, Molimard M.
    NPJ Prim Care Respir Med. 2018
  54. [Benzodiazepine use and misuse in France]
    Bénard-Laribière A, Pariente A.
    Presse Med. 2018
  55. [Use and misuse of benzodiazepines out of France]
    Tournier M, Pariente A, Bégaud B, Bénard-Laribière A.
    Presse Med. 2018
  56. [Use and misuse of benzodiazepines in patients with psychiatric disorders]
    Panes A, Fourrier-Réglat A, Verdoux H, Tournier M.
    Presse Med. 2018
  57. [Should the duration of treatment be limited using benzodiazepines?]
    Vorspan F, Barré T, Pariente A, Montastruc F, Tournier M.
    Presse Med. 2018
  58. children: A pilot study.
    Raherison C, Baldi I, Pouquet M, Berteaud E, Moesch C, Bouvier G, Canal-Raffin M.
    Environ Res. 2018
  59. Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes.
    Salvo F, Faillie JL.
    Therapie. 2018
  60. Pharmacoepidemiology of non-steroidal anti-inflammatory drugs.
    Moore N, Duong M, Gulmez SE, Blin P, Droz C.
    Therapie. 2018
  61. Comparative effectiveness and safety of standard or reduced dose dabigatran versus rivaroxaban in non-valvular atrial fibrillation.
    Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
    Clin Pharmacol Ther. 2018
  62. Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.
    Panes A, Pariente A, Bénard-Laribière A, Lassalle R, Dureau-Pournin C, Lorrain S, Tournier M, Fourrier-Réglat A.
    Eur Arch Psychiatry Clin Neurosci. 2018
  63. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: a nationwide database cohort study.
    Blin P, Samama CM, Sautet A, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Mismetti P, Moore N.
    Pharmacol Res. 2018
  64. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Gouverneur A, Coutureau J, Jové J, Rouyer M, Grelaud A, Duc S, Gérard S, Smith D, Ravaud A, Droz C, Bernard MA, Lassalle R, Forrier-Réglat A, Noize P; ETNA study group and the EREBUS study group.
    Clin Colorectal Cancer. 2018
  65. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P, Dureau-Pournin C, Benichou J, Bonello L, Dallongeville J, Danchin N, Falissard B, Thomas-Delecourt F, Jové J, Lassalle R, Droz C, Moore N.
    Atherosclerosis. 2018
  66. Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France.
    Bénard-Laribière A, Noize P, Girodet PO, Lassalle R, Dureau-Pournin C, Droz-Perroteau C, Fourrier-Réglat A, Salvo F, Bezin J, Pariente A; DRUGS-2M study group.
    Therapie. 2018